ARCELLX logo

ARCELLX Funding & Investors

Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Company's proprietary ARC-sparX platform separates the tumor-recognition and tumor-killing functions of conventional CAR-T cell therapies: (1) sparX (soluble protein antigen-receptor X-linkers) proteins recognize and bind specific antigens on diseased cells and flag those cells for destruction; and (2) ARC-T (Antigen Receptor Complex-T) cells bind the sparX proteins and kill the flagged cells. Arcellx has developed a collection of sparX proteins that bind different cell surface antigens. Administration of alternate sparX proteins can redirect ARC-T cells to different disease antigens to potentially address relapsed and refractory disease due to tumor heterogeneity or antigen escape. Additionally, ARC-T cell activity can be curbed as needed by controlling the dose and frequency of sparX administration.

arcellx.com

Total Amount Raised: $422,000,000

ARCELLX Funding Rounds

  • Post Ipo Equity

    $100,000,000

    Post Ipo Equity Investors

    Kite Pharma
  • Post Ipo Equity

    $112,000,000

  • Post Ipo Equity

    $9,999,986

  • Series C

    $115,000,000

    Series C Investors

    Novo Holdings
    Sr One
    New Enterprise Associates (NEA)
    Soleus Capital Management
    Suvretta Capital Management
    Takeda Ventures
    Sixty Degree Capital
    Adage Capital Management
    LG Technology Ventures
    Clough Capital Partners
    Samsara BioCapital
    CaaS Capital Management
    Asymmetry Ventures
    Surveyor Capital
    Terra Magnum Capital Partners (""""TMCP"""")""
    Cambrian
    CAM Capital
  • Series B

    $85,000,000

    Series B Investors

    Mirae Asset Venture Investment
    Novo Holdings
    Sr One
    Quan Capital
    Mirae Asset Capital
    New Enterprise Associates (NEA)
    Aju IB Investment
    Takeda Ventures
    LG Technology Ventures
    Solasta Ventures
    Clough Capital Partners
    JVC Investment Partners
Funding info provided by Diffbot.